

Silo Pharma, Inc. (Nasdaq: SILO) is a developmental stage biopharmaceutical company developing novel therapeutics and drug delivery systems that address underserved central nervous system (CNS) conditions including stress-induced psychiatric disorders, chronic pain, and neurological diseases. The Company's lead program, SPC-15, is a nose-to-brain intranasal formulation targeting PTSD and stress-induced anxiety disorders. Concurrent investigational new drug (IND)-enabling GLP (Good Laboratory Practice)-compliant studies in progress could provide the final pre-clinical data needed to advance SPC-15 to first-in-human clinical trials. Silo Pharma's next drug in development is SP-26, a time release ketamine-loaded implant for fibromyalgia and chronic pain relief. Two preclinical programs are underway for neurological diseases: SPC-14, an intranasal compound for the treatment of Alzheimer's disease (AD), and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). Columbia University has granted Silo exclusive worldwide rights to further develop, manufacture, and commercialize SPC-15 and SPC-14. Silo intends to utilize the FDA's streamlined 505(b)(2) pathway for SPC-15 and SP-26, which would shorten clinical timelines and reduce drug development costs.

Investment Highlights



Clear timeline to first-in-human clinical trials for lead asset SPC-15; final preclinical studies underway.



Exclusive global licenses granted by Columbia University to further develop, manufacture, and commercialize SPC-15 and SPC-14 worldwide.



Streamlined 505(b)(2) regulatory pathway for FDA drug approval planned for top two drug candidates.



Diversified pipeline of novel IP-protected technologies and assets showing promise in underserved rare disease, neurological, and mental health indications.



Disruptive market potential in central nervous system therapeutics industry; projected CAGR of 10.5% for CNS drugs during the period 2025 (~\$155.5 B) to 2034 (~\$381.3 B)¹.



Assets well-protected by strong IP, with extensive issued and pending patents.



Sufficient capital resources to support upcoming catalysts; prudent use of capital for drug development; zero debt.



Leadership with expertise in drug development and licensing, asset acquisition, biotech management, capital markets, and finance.

¹Polaris Market Research, Central Nervous System Therapeutics Market Growth, Trends, Global Forecast, 2025-2034

Development Timeline

Drug and Category	Indication	Optimization/ Proof of Concept	Preclinical	Phase I	Phase II	Phase III	Launch	Catalysts
SPC-15 <i>Mental Health</i>	Stress-Induced Affective Disorders	[Progress bar]						IND expected in 2025
SP-26 <i>Chronic Pain</i>	Fibromyalgia	[Progress bar]						March 2025 data
SPC-14 <i>Neurology</i>	Alzheimer's Disease (AD)	[Progress bar]						2025 data
SPU-16 Peptide <i>Neurology</i>	Multiple Sclerosis (MS)	[Progress bar]						2025 data

Under-Addressed Medical Needs: 4 Novel Drug Candidates

Mental Health

SPC-15 | Intranasal PTSD treatment

- Selective intranasal drug compound (non-psychedelic)
- Patented nose-to-brain delivery bypasses blood-brain barrier
- Direct, heightened drug concentration in the brain
- Optimized patient safety and therapeutic delivery

Neurology

SPC-14 | Alzheimer's Disease

- Potential to improve and restore cognitive and memory function

SPU-16 | CNS homing peptide

- Directly targets damaged tissue and inflammation in spinal cord

Chronic Pain

SP-26 | Non-opioid pain solution

- Ketamine-based therapeutic implant targeting fibromyalgia
- Self-administered treatment
- Safely regulated dosage and time release

2025 Recent Announcements

February 26 — Silo Pharma Granted U.S. Patent for Novel Intranasal Post-Traumatic Stress Disorder Treatment

February 18 — Silo Pharma Expands Intellectual Property Portfolio with Provisional Patent Filing for Innovative SPC-15 Combination Treatment

February 11 — Silo Pharma Announces Positive Initial Pharmacokinetic, Safety, and Tolerability Study of SP-26 for Chronic Pain and Fibromyalgia

January 22 — Silo Pharma Advances Intellectual Property Portfolio with Provisional Patent Filing for PTSD Treatment

January 8 — Silo Pharma Awarded US Patent for Groundbreaking PTSD Treatment and Prepares for SPC-15 Clinical Trial

January 2 — Silo Pharma Issues Letter to Shareholders Detailing Development Progress and Potential for Lead Assets Targeting PTSD and Chronic Pain

Leadership



Eric Weisblum, Founder and CEO

- 20+ years investing, building and managing businesses
- Prior president of Sableridge Capital
- Former board member of Aikido Pharma., a Nasdaq-listed biotech company focused on the commercialization of oncology



Daniel Ryweck CPA, CFO

- Certified Public Accountant
- Formerly chief compliance officer of Mill City Ventures III Ltd, interim chief financial officer of Sun BioPharma, Inc., and director of Dala Petroleum Corp.



James Kuo, M.D., MBA, VP of R&D

- Current managing director of Athena Bioventures
- Formerly held executive positions in private and listed bioscience companies in the U.S., Canada, and Europe
- Chairman of the Board of ImmunoPrecise Antibodies and board director of Tryp Therapeutics
- Former CEO of Tryp Therapeutics, Synthetic Biologics, BioMicro Systems, and Discovery Laboratories

Market Snapshot

Share Price
\$1.30 (3/12/25)

52-Wk. Range
\$0.77 - \$4.50

Avg. Vol.
3.2M

Shares O/S
4.8M

Market Cap
\$5.8M

Price and volume quotes from Yahoo! Finance

Analyst Coverage

Laidlaw & Company.

Yale Jen

Silo Pharma, Inc. | 677 N. Washington Blvd., Sarasota, FL 34236
Investor Relations Contact: 800-705-0120 | investors@silopharma.com

Forward-Looking Statements: This fact sheet contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of words "could", "believe", "anticipate", "intend", "estimate", "expect", "may", "continue", "predict", "potential" and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual results of Silo Pharma, Inc. ("Silo" or "the Company") to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company's technology platforms, retaining and expanding the Company's customer base, fluctuations in consumer spending on the Company's products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this fact sheet, whether as a result of new information, future events or otherwise, after the date of this document or to reflect the occurrence of unanticipated events except as required by law.